On September 17, 2025, Tonix Pharmaceuticals announced the in-licensing of worldwide rights to TNX-4800, a monoclonal antibody targeting Lyme disease, developed by UMass Chan Medical School. This significant event aims to advance TNX-4800 through clinical trials toward a Biologics Licensing Application with the FDA.